Search Results

You are looking at 1 - 10 of 15 items for :

Clear All
Open access

Solène Castellnou, Alexandre Vasiljevic, Véronique Lapras, Véronique Raverot, Eudeline Alix, Françoise Borson-Chazot, Emmanuel Jouanneau, Gérald Raverot and Hélène Lasolle

corticotroph tumor (cabergoline or pasireotide). Pasireotide, a second-generation somatostatin analog, acting on somatostatin receptor (SST) subtype 1,2,3 and 5, is the only approved pituitary-targeting drug for the treatment of Cushing’s disease ( 11 , 12

Open access

Vito Francic, Martin Keppel, Verena Schwetz, Christian Trummer, Marlene Pandis, Valentin Borzan, Martin R Grübler, Nicolas D Verheyen, Marcus E Kleber, Graciela Delgado, Angela P Moissl, Benjamin Dieplinger, Winfried März, Andreas Tomaschitz, Stefan Pilz and Barbara Obermayer-Pietsch

and thereby inhibiting the effects of IL-33/ST2 signalling ( 4 ). This protein has been shown to be a promising prognostic cardiovascular biomarker ( 5 ). Elevated levels of sST2 have been associated with poor prognosis in myocardial infarction ( 6

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

patients that are resistant to first-generation agents ( 15 ). It has a high affinity for multiple SSTs, including SST2, SST3 and SST5, which permits significantly improved control in those resistant to octreotide/lanreotide ( 16 ). Despite the well

Open access

Sara Storvall, Helena Leijon, Eeva Ryhänen, Johanna Louhimo, Caj Haglund, Camilla Schalin-Jäntti and Johanna Arola

as with β-adrenergic and opioid receptors, which, depending on the receptor type, can inhibit or enhance the effects of SST. There are five known SST subtypes: SST 1 , SST 2 , SST 3 , SST 4 and SST 5 . Through alternative splicing, two variants of

Open access

Stefan Schulz, Anika Mann, Benjamin Novakhov, Hugh D Piggins and Amelie Lupp

polyclonal antibodies. Recently, we have extensively characterised three novel rabbit MABs against the sst2A receptor, the sst5 receptor and the sst3 receptor named UMB1, UMB4 and UMB5. We have shown that these antibodies selectively detect their cognate

Open access

Małgorzata Fuksiewicz, Maria Kowalska, Agnieszka Kolasińska-Ćwikła, Jarosław B Ćwikła, Łukasz Sawicki, Katarzyna Roszkowska-Purska, Joanna Drygiel and Beata Kotowicz

for targeted treatment using SST receptor analogues. An additional feature is the release of non-specific markers, such as CgA ( 5 , 15 , 16 ). The CgA expression has been confirmed both in neuroendocrine tumours and other neoplasms, such as breast

Open access

Adrian F Daly, David A Cano, Eva Venegas-Moreno, Patrick Petrossians, Elena Dios, Emilie Castermans, Alvaro Flores-Martínez, Vincent Bours, Albert Beckers and Alfonso Soto-Moreno

patients may be resistant to somatostatin analogs (SSA) that target the somatostatin receptor subtype 2 (SST2), while a small proportion of prolactinoma patients may not respond to labeled doses of dopamine agonists (DA). Hence, multimodal therapy involving

Open access

Hélène Lasolle, Amandine Ferriere, Alexandre Vasiljevic, Sandrine Eimer, Marie-Laure Nunes and Antoine Tabarin

, pegvisomant (PEG), is a second-line treatment which normalizes IGF-1 plasma levels in 60–70% ( 5 ) of patients in follow-up registries and up to 97% in single-center series ( 6 ). The dopamine D2-receptor agonist, cabergoline, is an alternative to 1 GSSA

Open access

Morten Ruge, Tea Skaaby, Anna-Maria Andersson and Allan Linneberg

phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction, reduced muscle mass and strength, depressed mood, decreased energy and low bone mass ( 2 ). As the mean age of the populations in the Western world is rising, the prevalence of this condition is

Open access

Filippo Ceccato, Diego Cecchin, Michele Gregianin, Giacomo Ricci, Cristina Campi, Filippo Crimì, Marta Bergamo, Annibale Versari, Carmelo Lacognata, Federico Rea, Mattia Barbot and Carla Scaroni

H Redmann A Walz MK Schmid KW Mann K Petersenn S . Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland . Hormone and Metabolic Research 2005 37 722